Cost-Effectiveness Research

Featured

News
Obinutuzumab Cost-Effective vs Rituximab Biosimilars for Previously Untreated FL
For the first-line treatment of FL, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab-abbs or rituximab-pvvr plus chemotherapy in the United States.
Conference Coverage
Out-of-Pocket Cost-Effectiveness of Frontline Maintenance Strategies for Advanced Ovarian Cancer
In comparison with a biomarker-based strategy, first-line niraparib-for-all maintenance therapy is cost-effective for…
Conference Coverage
Minimally Invasive Surgery Cost-Effective vs Laparotomy for Early-Stage Ovarian Cancer
Minimally invasive surgery is cost-effective compared with laparotomy for suspicious ovarian masses, even though it is…
News
Cost-Effectiveness of KTE-X19 vs Standard of Care for Relapsed/Refractory MCL
KTE-X19 is a potentially cost-effective alternative to the current standard of care for relapsed/refractory MCL.
Videos
Neoadjuvant Immune Checkpoint Inhibitors Unlikely Cost-Effective for Muscle-Invasive Bladder Cancer
Ali Khaki, MD, discusses results from a cost-effectiveness analysis comparing neoadjuvant immune checkpoint inhibition…

News

Obinutuzumab Cost-Effective vs Rituximab Biosimilars for Previously Untreated FL
Cost-Effectiveness of KTE-X19 vs Standard of Care for Relapsed/Refractory MCL
Cost-Effectiveness of Selective Internal Radiotherapy vs Sorafenib in HCC
Targeted Genetic Testing Cost-Effective for Breast and Ovarian Cancer

Interviews

Discussing Biosimilars: Barriers and Cost-Effectiveness

Blog

PCORI to Incorporate Cost But Not Cost-Effectiveness in its New Principles

Videos

Neoadjuvant Immune Checkpoint Inhibitors Unlikely Cost-Effective for Muscle-Invasive Bladder Cancer

Podcast

Is CAR-T Therapy Comparable to Past Innovative Therapies in Regard to Health Outcomes, Cost-Effectiveness?

Conference Coverage

Nivolumab Plus Ipilimumab Cost-Effective for Intermediate or Poor Risk RCC
Back to Top